

Johnson & Johnson

Pharmaceuticals Business Review





Louise Mehrotra

Vice President

Investor Relations

Johnson & Johnson



Note on Forward-looking Statements

These presentations contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events.

If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company’s expectations and projections.

Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents obtained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment.

Note on Forward-looking Statements

A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 2008. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from the Company.

The Company does not undertake to update any forward-looking statements as a result of new information or future events or developments.

New Molecular Entities

These presentations contain statements about new molecular entities (“NMEs”) and other medicines or line extensions in various stages of development. These statements are based on the Company’s current knowledge of the status of development of these NMEs, medicines and line extensions and are subject to the challenges and difficulties inherent in product development. The Company assumes no obligation to update any statements regarding these NME, medicines or line extensions as a result of new information or future events or developments.

In biopharmaceuticals, there are higher possibilities of encountering infringement claims by competitors with respect to patents or other intellectual property rights. The Company assumes no obligation to update any statements as a result of new information or future events or developments.

Acknowledgement of Partnerships, Collaborations and Licensing Arrangements

During the course of today's presentations, we will discuss a number of products and compounds developed in collaboration with partners or licensed from other companies. Following is an acknowledgement of those relationships.

Neuroscience: INVEGA® Sustenna developed in collaboration with Elan Corporation, plc; RISPERDAL® CONSTA® developed in collaboration with Alkermes, Inc.; NUCYNTA™ co-developed with Grunenthal GMBH; COMFYDE™ licensed from SK-Bio Pharmaceuticals; Anti-NGF licensed from Amgen, Inc.

Cardiovascular/Metabolism: PRILIGY® developed in collaboration with PPD-GenuPro; Rivaroxaban co-developed with Bayer HealthCare; Canagliflozin developed in collaboration with Mitsubishi-Tanabe Pharmaceutical Corporation; Glucose-dependent insulinotropic receptor licensed from Arena Pharmaceuticals, Inc.

Infectious Diseases: ZEVTERA™/ZEFTERA™ developed in collaboration with Basilea Pharmaceutica; DORIBAX™ developed in collaboration with from Shionogi & Co.; Telaprevir developed in collaboration with Vertex Pharmaceuticals Incorporated; TMC435 developed in collaboration with Medivir AB.

Immunology: REMICADE® and SIMPONI™ marketing partners are Schering Plough Corporation and Mitsubishi Tanabe Pharma Corporation; ReoPro® marketing partner is Eli Lilly. CNTO 888 developed using Morphosys's HuCAL technology

Oncology: VELCADE® developed in collaboration with Millennium Pharmaceuticals, The Takeda Oncology Company; YONDELIS® developed in collaboration with PharmaMar SAU; DACOGEN® developed in collaboration with Eisai Corporation of North America; PROCRI™/EPREX® licensed from Amgen Inc.

Johnson & Johnson

